Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Official title

Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Overview

This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) to a split-dose CHP chemotherapy backbone will improve outcomes for elderly patients with a new diagnosis of diffuse large B-cell lymphoma.

Detailed description

This trial combines two novel agents, mosunetuzumab subcutatneous and polatuzumab vedotin (Mosun-Pola), with cytotoxic chemotherapy while allowing de-escalation in rapidly responding patients. After completing the first two cycles of Mosun-Pola-SD-CHP therapy, subjects will undergo an interim response assessment with positron emission tomography (PET) / computed tomography (CT) and minimal residual disease (MRD) testing (ClonoSEQ; Adaptive Biotechnology) prior to Cycle 3A. Patients who are interim PET-negative and MRD-negative will be placed on an abbreviated treatment regimen, where they will receive Mosun-Pola-SD-CHP therapy for only four cycles.

Interventions

• Drug Polatuzumab Vedotin
  A combination of a monoclonal antibody and a chemotherapy drug.
• Drug Mosunetuzumab
  A monoclonal antibody.
• Drug Cyclophosphamide
  Chemotherapy drug, alkylating agent.
• Drug Doxorubicin
  Chemotherapy drug, anthracycline antibiotic.
• Drug Prednisone
  Steroid, anti-inflammatory
• Other Pegfilgrastim
  Granulocyte stimulating factor, biologic response modifier.

Primary outcome measures

• Complete Response [Time frame: Up to six months.]

Secondary outcome measures (10)

• Partial Response [Time frame: Up to six months]
• Duration of Response [Time frame: Up to 60 months]
• Overall Survival [Time frame: 2 years]
• Adverse Events [Time frame: Up to 7 months]
• Study therapy completion [Time frame: Up to 6 months]
• Eligibility for abbreviated therapy [Time frame: 56 days]
• Eligibility for full therapy [Time frame: 56 days]
• CRS or ICANS [Time frame: 28 days]
• Minimal residual disease at Cycle 3 [Time frame: 56 days]
• Minimal residual disease at end of study treatment [Time frame: Up to six monts]

Eligibility criteria

Inclusion criteria

• Patients aged 70-74 who are determined to be unfit or frail by the Cumulative Illness Rating Scale-Geriatric (CIRS-G) score with 5-8 comorbid conditions scored 2 or more than 1 comorbidity scored 3-4 are allowed.
• Newly diagnosed, untreated, biopsy-proven CD20 positive diffuse large B-cell lymphoma (DLBCL) (including high-grade B-cell lymphoma and T-cell/histiocyte-rich large B-cell lymphoma). Patients with discordant bone marrow (i.e., involved by low-grade/indolent non-Hodgkin lymphoma) are eligible. Patients with transformed DLBCL from underlying low-grade disease are eligible. Patients with composite DLBCL and concurrent low-grade lymphoma are eligible. Patients with prior treatment for low-grade NHL with non-anthracycline based regimens are eligible.

a. Short-course prednisone or equivalent steroid for symptom management is allowable for up to seven days.

• Measurable disease by positron emission tomography (PET) / computed tomography (CT) using the Lugano criteria (lymph node >1.5 cm or extranodal site >1.0 cm).
• Adequate biospecimen sample that meets current Adaptive Clonality ID Test specimen requirements for DLBCL.

a. Note: the preferred ID specimen type is a formalin-fixed paraffin-embedded (FFPE) lymph node biopsy, either FFPE slides or scrolls, targeting 40 microns of material.

• Left ventricular ejection fraction ≥50% by echocardiography or multigated acquisition (MUGA) scan.
• Karnofsky Performance Score ≥50 or Eastern Cooperative Oncology Group (ECOG) scan 0-2.
• Ann Arbor Stage II bulky, III, or IV disease.
• Minimum life expectancy greater than 3 months (should be explicitly documented by the enrolling investigator).
• Negative HIV test. Individuals with a positive HIV test at screening are eligible provided that, prior to enrollment, they are stable on antiretroviral therapy for at least 4 weeks, have a CD4 count ≥200/µL, and have an undetectable viral load, and have not had a history of opportunistic infection attributable to acquired immunodeficiency syndrome (AIDS) within the last 12 months.
• For patients with hepatitis B virus antigen (HBsAg) or core antibody (HBcAb) seropositivity, patients must have a negative hepatitis B viral load and an appropriate prophylaxis plan must be in place during chemotherapy therapy treatment. For all patients that are hepatitis B core antibody positive, they should take entecavir prophylaxis (0.5 mg by mouth daily) until 1 year from completion of chemotherapy. Hepatitis B viral load should be checked on these patients prior to starting chemotherapy and every 3 months thereafter if initial hepatitis B viral load is negative (±1 week if chemotherapy cycle is delayed). If hepatitis B viral load is positive, hepatology or ID referral is recommended, and hepatitis B viral load should be checked monthly and every 3 months for 12 months after end of treatment.
• For patients with hepatitis C Ab positivity, a viral load must be checked and negative for enrollment.
• Negative SARS-CoV-2 antigen or polymerase chain reaction (PCR) test within 7 days prior to enrollment.
• Had at least one dose of a COVID-19 vaccine approved or authorized for emergency use by the FDA.
• Intrathecal chemotherapy for central nervous system prophylaxis can only be given at the discretion of the primary oncologist.

a. Note: patients who received high-dose methotrexate are not eligible for the study.

• For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm, as defined below:

• With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for 6 months after the final dose of Mosun-Pola-SD-CHP. Male participants must refrain from donating sperm during this same period.
• The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the Informed Consent Form.
• Ability to understand a written informed consent document, and the willingness to sign it.
• In the opinion of the enrolling investigator, subject must be deemed able to comply with the study intervention.

Exclusion criteria

• Prior treatment for DLBCL with chemotherapy, immunotherapy, and biologic therapy.
• Current Grade >1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease.
• Prior allogeneic or autologous stem cell transplant.
• Prior solid organ transplant.
• Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).
• Known or suspected chronic active Epstein-Barr Virus (EBV) infection.
• History of progressive multifocal leukoencephalopathy (PML).
• Current or within 6 months of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
• Patients with SARS-CoV-2 antigen or PCR testing positivity within 30 days prior to Cycle 1 Day 1.

a. Any patient with documented SARS-CoV-2 infection within 6 months prior to planned Cycle 1 Day 1 must have no persistent respiratory symptoms, no evidence of residual sequelae, and have a negative PCR test for SARS-CoV-2.

• Administration of a live, attenuated vaccine within 4 weeks before start of study therapy or anticipation that such a live, attenuated vaccine will be required during the study.
• On immunosuppressant therapy for an active autoimmune disease, including, but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

a. Exceptions may be made for patients with a remote history of or well-controlled autoimmune disease, excluding patients on systemic immunosuppression for autoimmune disease, or patients who received such immunosuppression within 1 year prior.

• Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
• Recent major surgery within 4 weeks before the start of C1D1 with the exception of lymph node biopsies for diagnosis.
• Prior treatment with radiotherapy within 2 weeks prior to Cycle 1 Day 1.

• If patients have received radiotherapy within 4 weeks prior to the initiation of study treatment, patients must have at least one measurable lesion outside of the radiation field to be eligible.
• Patients who have only one measurable lesion that was previously irradiated but subsequently progressed are eligible.
• History of previous anthracycline exposure.
• CNS or meningeal involvement at diagnosis.
• Richter's Transformation (e.g., DLBCL transformed from an underlying chronic lymphocytic leukemia (CLL) ).
• Patients with primary mediastinal large B cell lymphoma (PMBCL).
• Creatinine clearance <40 mL/min by Cockcroft-Gault.
• Poor hepatic function, defined as total bilirubin concentration greater than 3.0 mg/dL or transaminases over 4 times the maximum normal concentration, unless these abnormalities are felt to be related to the lymphoma (which should be explicitly documented by the enrolling physician).
• Pulmonary dysfunction, defined as receiving supplemental O2 or significant pulmonary comorbidities (e.g., history of pneumonitis, severe chronic obstructive pulmonary disease (COPD) ).
• Significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease.
• Active infectious disease (if patient is on medications for such situations, enrolling physician should explicitly document justification of meeting this criteria).
• Known concurrent bone marrow malignancies (e.g., myelodysplastic syndrome) or poor bone-marrow reserve, defined as neutrophil count less than 1.5 × 10\^9/L or platelet count less than 100 × 10\^9/L, unless caused by bone-marrow infiltration with lymphoma.
• History of a second concurrent active malignancy or prior malignancy which required chemotherapy treatment within the preceding 2 years (other than cured basal or squamous cell carcinoma, low-risk prostate cancer on observation, and other in situ carcinomas that were completely treated).
• Treatment with any investigational drug within 30 days before enrollment.
• Unable or unwilling to sign consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Froedtert Hospital & the Medical College of Wisconsin — Milwaukee

Identifiers

NCT: NCT06594939 · PRO00056497

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗